S&P 500: 662.29 -0.6% NASDAQ 100: 593.72 -0.6% Dow Jones: 466.41 -0.2%

Andreas Halvorsen’s BBIO Holdings & Trades

First Buy
Q2 2019
Duration Held
27 Quarters
Largest Add
Q2 2019
+26.62 M Shares
Current Position
14.39 M Shares
$1.1 B Value

Andreas Halvorsen's BBIO Position Overview

Andreas Halvorsen (via Viking Global Investors Lp) currently holds 14.39 M shares of BridgeBio Pharma, Inc. (BBIO) worth $1.1 B, representing 2.92% of the portfolio. First purchased in 2019-Q2, this long-term strategic position has been held for 27 quarters.

Based on 13F filings, Andreas Halvorsen has maintained a strategic position in BBIO, demonstrating sustained confidence in this investment. Largest reduction occurred in Q2 2025, reducing 3.5 M shares.

Analysis based on 13F filings available since 2013 Q2

Andreas Halvorsen's BridgeBio Pharma (BBIO) Holding Value Over Time

Track share changes against reported price movement

Quarterly BridgeBio Pharma (BBIO) Trades by Andreas Halvorsen

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q4 2025 -1.58 M Reduce 9.91% 14.39 M $76.49
Q3 2025 -2.58 M Reduce 13.89% 15.98 M $51.94
Q2 2025 -3.5 M Reduce 15.87% 18.56 M $43.18
Q1 2025 -3.07 M Reduce 12.20% 22.06 M $34.57
Q3 2023 -1.5 M Reduce 5.63% 25.12 M $26.37
Q2 2019 +26.62 M New Buy 26.62 M $26.97

Andreas Halvorsen's BridgeBio Pharma Investment FAQs

Andreas Halvorsen first purchased BridgeBio Pharma, Inc. (BBIO) in Q2 2019, acquiring 26,620,991 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Andreas Halvorsen has held BridgeBio Pharma, Inc. (BBIO) for 27 quarters since Q2 2019.

Andreas Halvorsen's largest addition to BridgeBio Pharma, Inc. (BBIO) was in Q2 2019, adding 26,620,991 shares worth $717.97 M.

According to the latest 13F filing for Q4 2025, Andreas Halvorsen's firm, Viking Global Investors Lp, owns 14,393,934 shares of BridgeBio Pharma, Inc. (BBIO), valued at approximately $1.1 B.

As of the Q4 2025 filing, BridgeBio Pharma, Inc. (BBIO) represents approximately 2.92% of Andreas Halvorsen's publicly disclosed stock portfolio, making it one of their key holdings.

Andreas Halvorsen's peak holding in BridgeBio Pharma, Inc. (BBIO) was 26,620,991 shares, as reported at the end of Q2 2019.